141 related articles for article (PubMed ID: 25792842)
21. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
22. [Effectiveness of pegylated liposomal doxorubicin in relapsed ovarian cancer].
Lehoczky O; Pulay T
Magy Onkol; 2006; 50(3):261-4. PubMed ID: 17099788
[TBL] [Abstract][Full Text] [Related]
23. Erratum: Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: application to the passive encapsulation of [(14)C]-doxorubicin [Corrigendum].
Nanotechnol Sci Appl; 2016; 9():47. PubMed ID: 27536080
[TBL] [Abstract][Full Text] [Related]
24. Erratum: Insights into the antibacterial mechanism of PEGylated nano-bacitracin A against
Int J Nanomedicine; 2019; 14():337. PubMed ID: 30655666
[TBL] [Abstract][Full Text] [Related]
25. Erratum: Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant [Corrigendum].
Int J Nanomedicine; 2018; 13():4845. PubMed ID: 30214192
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
27. Erratum: COUP-TFII promotes colorectal carcinoma resistance to doxorubicin involving inhibition of epithelial-mesenchymal transition.
Wang X; Jiang R; Cui E; Feng W; Guo H; Gu D; Tang C; Xue T; Bao Y
Am J Transl Res; 2018; 10(8):2747-2748. PubMed ID: 30210712
[TBL] [Abstract][Full Text] [Related]
28. A comparison of overall survival with 40 and 50mg/m
Nakayama M; Kobayashi H; Takahara T; Nishimura Y; Fukushima K; Yoshizawa K
Gynecol Oncol; 2016 Nov; 143(2):246-251. PubMed ID: 27612976
[TBL] [Abstract][Full Text] [Related]
29. Safety aspects of pegylated liposomal doxorubicin in patients with cancer.
Alberts DS; Garcia DJ
Drugs; 1997; 54 Suppl 4():30-5. PubMed ID: 9361959
[TBL] [Abstract][Full Text] [Related]
30. Pegylated liposomal doxorubicin in the treatment of breast cancer.
O'Shaughnessy JA
Clin Breast Cancer; 2003 Dec; 4(5):318-28. PubMed ID: 14715106
[TBL] [Abstract][Full Text] [Related]
31. Recurrent ovarian undifferentiated carcinoma resembling hepatoid morphology treated with pegylated liposomal doxorubicin and bevacizumab.
Ishiguro T; Kashima K; Yachida N; Motoyama T; Enomoto T
J Obstet Gynaecol Res; 2017 May; 43(5):957-961. PubMed ID: 28422375
[TBL] [Abstract][Full Text] [Related]
32. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.
Ryan GM; Kaminskas LM; Bulitta JB; McIntosh MP; Owen DJ; Porter CJH
J Control Release; 2013 Nov; 172(1):128-136. PubMed ID: 23954628
[TBL] [Abstract][Full Text] [Related]
33. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
34. The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial.
Miyahara D; Ueda T; Katsuda T; Maehara M; Fukagawa S; Miyata K; Nam SO; Kondo H; Miyamoto S
Anticancer Res; 2015 Aug; 35(8):4521-5. PubMed ID: 26168496
[TBL] [Abstract][Full Text] [Related]
35. Erratum: Corrigendum: Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective.
Curr Oncol; 2011 Dec; 18(6):303. PubMed ID: 22184492
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
37. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME; Curiel T; Gómez JG; Jorge M
Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
[TBL] [Abstract][Full Text] [Related]
38. Erratum: Integrating complementary/alternative medicine into primary care: evaluating the evidence and appropriate implementation [Corrigendum].
Int J Gen Med; 2016; 9():19. PubMed ID: 26929660
[TBL] [Abstract][Full Text] [Related]
39. [Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin].
Khokhlova SV; Cherkasova MV; Orel NF; Limareva SV; Bazaeva IIa; Gorbunova VA
Vestn Ross Akad Med Nauk; 2013; (11):115-21. PubMed ID: 24640740
[TBL] [Abstract][Full Text] [Related]
40. [Safety and efficacy of pegylated liposomal Doxorubicin and Carboplatin on platinum-sensitive recurrent epithelial ovarian cancer].
Nishio S; Ushijima K; Shimizu T; Tachibana T; Nasu H; Aiko K; Kawano R; Kurokawa Y; Sumino Y; Yokomine M; Takemoto S; Kamura T
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2539-43. PubMed ID: 24335366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]